Showing 2644 results
- Featured News /
Novartis is committed to reimagining the fight against Chagas Disease and advocating for an integrated, end-to-end care approach.
- Media Release /Six African nations will join a partnership pioneered in Ghana using technology to track and better tackle sickle cell disease (SCD) Includes expanded rollout of an app to track babies diagnosed…
- Media Release /Kisqali is the only CDK4/6 inhibitor with consistent overall survival (OS) benefit seen across all three Phase III trials, with the longest median OS benefit ever reported for HR+/HER2- mBC1-10 OS…
- Media Release /Biomarker analysis from Phase III SOLAR-1 study shows Piqray plus fulvestrant had clinical benefit regardless of presence of ESR1 mutations and genes implicated in CDK4/6i resistance1 Piqray plus…
- Media Release /Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in…
- Featured News /
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
- Story /
Raising awareness of the ways in which prostate cancer can affect the sexual minority and gender minority communities.
- Media Release /Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-…
- Story /
Novartis’ Don Ganem tapped as a scientific advisor for the Chan Zuckerberg Biohub
- Story /
Pagination
- ‹ Previous page
- 1
- …
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- …
- 265
- › Next page